CARMAL: A Potential Drug Target for CAD (G102724566)

Target Name: CARMAL

NCBI ID: G102724566

CARMAL

Other Name(s): coronary artery disease region linked MFGE8 regulatory lncRNA | CARMAL variant X4 | Coronary artery disease region linked MFGE8 regulatory lncRNA, transcript variant X4

CARMAL: A Potential Drug Target for CAD

Coronary artery disease (CAD) is a leading cause of death worldwide, with over 170 million people having died from CAD since 2000. The most common type of CAD is myocardial infarction, which occurs when the blood flow to the heart is blocked, usually by a clot in a coronary artery.

Regulatory RNA (RNA) is a crucial molecule in the regulation of gene expression, and it has been identified as a potential drug target in the treatment of CAD. One of the RNA molecules that has been particularly well-studied in relation to CAD is MFGE8, a non-coding RNA molecule that has been shown to be involved in the regulation of gene expression in various tissues, including the heart.

CARMAL is a new RNA molecule that has been identified as a potential drug target for the treatment of CAD. It is a region linked MFGE8 (MFGE8-regulated gene expression) RNA molecule and has been shown to be involved in the regulation of gene expression in the heart.

The discovery of CARMAL

CARMAL was identified through a combination of RNA sequencing and bioinformatics analysis. The authors of a study published in the journal Nature used RNA sequencing to identify a new RNA molecule that was highly expressed in the hearts of mice and was showing different levels of expression in various tissues. They then used bioinformatics analysis to identify a cDNA molecule that encodes for this RNA and named it CARMAL.

CARMAL is a small RNA molecule that contains 1,184 amino acids and has a molecular weight of 21 kDa. It is composed of a single exon that is located in the 5'-end of the gene. The exon has a reading frame of 114 amino acids and includes a unique 5'-end that is different from the 3'-end.

CARMAL is expressed in various tissues and cells

CARMAL is expressed in a variety of tissues and cells in the body, including the heart, the kidneys, the liver, and the pancreas. It is also expressed in the placenta, which plays a crucial role in the development and growth of new tissues.

CARMAL is involved in the regulation of gene expression

CARMAL has been shown to be involved in the regulation of gene expression in various tissues and cells. One of the ways that CARMAL does this is by binding to specific DNA sequences and preventing them from being translated into proteins. This is known as RNA-protein interaction and is a common mechanism by which RNA molecules regulate gene expression.

CARMAL has also been shown to be involved in the regulation of gene expression in the heart. Studies have shown that CARMAL is highly expressed in the hearts of mice and that it is involved in the regulation of gene expression in these tissues.

CARMAL may be a drug target for the treatment of CAD

The results of the studies suggest that CARMAL may be a drug target for the treatment of CAD. By targeting the regulation of gene expression by CARMAL, researchers may be able to develop new treatments for CAD that specifically target this molecule.

The potential benefits of developing a drug target for CARMAL

The development of a drug target for CARMAL has the potential to revolutionize the treatment of CAD. By developing a drug that specifically targets CARMAL, researchers may be able to reduce the risk of CAD and improve the quality of life for patients.

Additionally, the development of a drug target for CARMAL may also have the potential to create new opportunities for the development of new treatments for other diseases. By studying the regulation

Protein Name: Coronary Artery Disease Region Linked MFGE8 Regulatory LncRNA

The "CARMAL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARMAL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets